Previous Close | 135.05 |
1-Year Change | 45.83% |
6-Months Change | 25% |
3-Months Change | -0.63% |
Moving Avg (50d) | 139.66 |
Moving Avg (200d) | 125.98 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 21.3B |
Beta (3-Years) | 1.38 |
Revenue Growth (ttm) | -4.98% |
Net Profit Margin (ttm) | -25.17% |
Return On Assets (ttm) | -11.1% |
EPS (ttm) | -7.1 |
PE Ratio (ttm) | -19.02 |
Dividend Yield | % |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Life Sciences Tools & Services |
Country: | United States |
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more... Wikipedia